Further from the article L.C. posted:
"Without some leukopheresis/immune-training process, a-la Dendreon or a specialized adjuvant, it is difficult to generate a vaccine to an endogenously found peptide. A MUC1 antibody or small molecule antagonist would make a lot more sense. Indeed, several companies are attempting to improve the immune response for prospective MUC1 vaccines as well as attempting targeted payload strategies for MUC1."
One of those aforementioned companies: Prima Biomed.
bad news for onty - stimuvax fails p3 trial, page-7
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.005(1.25%) |
Mkt cap ! $588.3M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.5¢ | 39.8¢ | $2.431M | 6.045M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6880 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 85353 | 3 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |